[A prospective cohort study on effects of levonorgestrel-releasing intrauterine system for adenomyosis with severe dysmenorrhea].

article OA: closed CC0 ⤵ 2 in-corpus citations
AI-generated summary by gemini-2.5-flash-lite, 2026-06-07

This prospective study found that levonorgestrel-releasing intrauterine system (LNG-IUS) significantly reduced pain scores in women with adenomyosis and severe dysmenorrhea.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by qwen3.7-flash, 2026-08-27 · read from full text

This prospective cohort study evaluated the efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS) in treating severe dysmenorrhea associated with adenomyosis. The research included 1,100 patients diagnosed via ultrasound, with a median follow-up period of 35 months, tracking pain scores, bleeding patterns, and adverse effects over time. Results demonstrated a significant and sustained reduction in visual analog scale pain scores from baseline to 60 months post-placement, with an accumulative continuation rate of 65% at five years. The authors noted that no specific factors could universally predict pain relief, and improvements were independent of menstrual pattern changes or side effects. This paper is centrally about adenomyosis — specifically assessing the long-term effectiveness of LNG-IUS for managing severe dysmenorrhea in this patient population.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: To investigate treatment effects of levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis with severe dysmenorrhea in a prospective cohort study. METHODS: From December 2006 to December 2014, patients of symptomatic adenomyosis diagnosed by transvaginal ultrasound in outpatient or inpatient clinics of Peking Union Medical College Hospital were given the treatment of LNG-IUS. Before and after placement of LNG-IUS, all the patients' parameters were recorded prospectively, including symptoms and scores of dysmenorrhea, menstruation scores, biochemical indicators, physical parameters, carrying status of LNG-IUS, menstruation patterns and adverse effects. Changes of scores and patterns of pain during follow-up were analyzed. RESULTS: Totally 1 100 women meets inclusion criteria, among which 640 cases (58.18%, 640/1 100) had severe dysmeorrhea, with median follow-up period of 35 months (range 1-60 months), and accumulative carrying rate of 65% at 60 months follow-up. After placement of LNG-IUS, scores of pain and ratio of severe dysmenorrhea had decreased significantly compared with baselines (all P<0.01), the scroes of visual analog scale (VAS) were 8.1±0.9, 5.5±2.4, 4.6±2.4, 3.3±2.2, 2.2±2.1, 2.2±1.8, 1.4±1.6 and 1.3±1.3 at 0, 3, 6, 12, 24, 36, 48 and 60 months respectively. During 36 months after placement of LNG-IUS, scores of pain had improved significantly compared with preceding period (all P0.05). CONCLUSION: LNG-IUS is effective for adenomyosis of severe dysmenorrhea. Improvement of pain is independent on patients characters, menstruation patterns or adverse effects.
Full text 2,809 characters · extracted from oa-doi-fallback · click to expand
LNG-IUS治疗子宫腺肌病相关重度痛经的前瞻性研究 A prospective cohort study on effects of levonorgestrel-releasing intrauterine system for adenomyosis with severe dysmenorrhea 摘要目的:在前瞻性队列研究中分析左炔诺孕酮宫内缓释系统(LNG-IUS)治疗子宫腺肌病相关重度痛经的效果及痛经缓解的预测因素。方法选择2006年12月至2014年12月在中国医学科学院北京协和医院妇产科门诊或住院部通过超声检查诊断为子宫腺肌病的重度痛经和(或)经量过多患者共1100例给予LNG-IUS治疗,在放置前后不同随访时点评估患者的痛经症状、疼痛评分、出血评分、生化指标、体格参数、LNG-IUS带器情况、月经模式以及不良反应,分析疼痛评分及分布的变化趋势、重度痛经缓解的预测因素以及与月经模式、不良反应的关系。结果符合入选标准的子宫腺肌病患者共1100例,其中重度痛经患者640例(58.18%,640/1100),中位随访时间35个月(范围1~60个月),在放置LNG-IUS后60个月时的累积续用率为65%。放置LNG-IUS后重度痛经患者的疼痛评分与放置前相比均显著下降(P均<0.01),放置前、放置后3、6、12、24、36、48和60个月的视觉模拟评分(VAS)分别为(8.1±0.9)、(5.5±2.4)、(4.6±2.4)、(3.3±2.2)、(2.2±2.1)、(2.2±1.8)、(1.4±1.6)、(1.3±1.3)分。放置LNG-IUS后重度痛经患者的比例与放置前相比显著下降(P均<0.01)。在放置LNG-IUS的36个月内,每个随访时点与前一随访时点比较,疼痛评分均有显著改善(P均0.05)。结论 LNG-IUS是治疗子宫腺肌病相关重度痛经的有效方案,痛经改善状态与患者的一般情况、治疗模式、月经变化或不良反应无关。 更多相关知识 abstractsObjective To investigate treatment effects of levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis with severe dysmenorrhea in a prospective cohort study. Methods From December 2006 to December 2014, patients of symptomatic adenomyosis diagnosed by transvaginal ultrasound in outpatient or inpatient clinics of Peking Union Medical College Hospital were given the treatment of LNG-IUS. Before and after placement of LNG-IUS, all the patients′parameters were recorded prospectively, including symptoms and scores of dysmenorrhea, menstruation scores, biochemical indicators, physical parameters, carrying status of LNG-IUS, menstruation patterns and adverse effects. Changes of scores and patterns of pain during follow-up were analyzed. Results Totally 1 100 women meets inclusion criteria, among which 640 cases (58.18%, 640/1 100) had severe dysmeorrhea, with median follow-up period of 35 months (range 1-60 months), and accumulative carrying rate of 65% at 60 months follow-up. After placement of LNG-IUS, scores of pain and ratio of severe dysmenorrhea had decreased significantly compared with baselines (all P<0.01), the scroes of visual analog scale (VAS) were 8.1 ± 0.9, 5.5 ± 2.4, 4.6 ± 2.4, 3.3 ± 2.2, 2.2 ± 2.1, 2.2 ± 1.8, 1.4 ± 1.6 and 1.3 ± 1.3 at 0, 3, 6, 12, 24, 36, 48 and 60 months respectively. During 36 months after placement of LNG-IUS, scores of pain had improved significantly compared with preceding period (all P0.05). Conclusion LNG-IUS is effective for adenomyosis of severe dysmenorrhea. Improvement of pain is independent on patients characters, menstruation patterns or adverse effects. More相关知识 - 浏览0 - 被引39 - 下载0 相似文献 - 中文期刊 - 外文期刊 - 学位论文 - 会议论文

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Outcome instruments

VAS-pain

Condition tags

dysmenorrheaadenomyosis

MeSH descriptors

Adenomyosis Contraceptive Agents, Female Intrauterine Devices, Medicated Levonorgestrel Adenomyosis Adult Contraceptive Agents, Female Contraceptive Agents, Female Dysmenorrhea Dysmenorrhea Dysmenorrhea Female Humans Levonorgestrel Levonorgestrel Menstruation Menstruation Pain Measurement Prospective Studies Severity of Illness Index

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

europepmc
last seen: 2026-09-14T06:17:53.580500+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:00.404924+00:00
License: CC0 · commercial use OK